SRRK: Scholar Rock Holding Corporation
Performance
SRRK +78.07%
Watchlist
Select an item
Summary
SRRK at a glance
SRRK returned +78.07% over the past year and +12.63% a year over five years. Its worst drop in that year was -34.04%, smaller than 49% of stocks on Redstone, and its Sharpe ratio of 1.23 beats 84% of stocks on Redstone. It pays no dividends.
Current Drawdown
-14.14%
Rolling Volatility
47.97%
Actions
Metrics
Risk Indicators
Alpha58.60%
Beta1.12x
Sharpe1.23
Sortino2.27
Omega1.25
Calmar2.29
Martin5.61
Profile
About SRRK
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab.
- Sector
- Health Care
- Industry
- Biological Products, (no Diagnostic Substances)
- Market cap
- $6.3B
- Listed
- May 2018
- Employees
- 289
- Headquarters
- Cambridge, MA
- Website
- scholarrock.com
Comparisons